Zydus Pharmaceuticals Inc is the US arm of Cadila Healthcare.
Net Sales are expected to decrease by 3.6 percent Y-o-Y (down 12.4 percent Q-o-Q) to Rs. 3,134.8 crore, according to Prabhudas Lilladher.
Geojit recommended hold rating on Cadila Healthcare with a target price of Rs 358 in its research report dated March 15, 2019.
Cadila Healthcare is going to launch over 40 products this year, said Chairman Pankaj Patel.
ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 370 in its research report dated February 08, 2019.
A bearish broadening follow through in Cadila Healthcare.
Prabhudas Lilladher recommended accumulate rating on Cadila Healthcare with a target price of Rs 362 in its research report dated February 07, 2019.
Macquarie upgraded Cadila Healthcare to 'Outperform' from'Neutral'.
Total revenue, however, rose to Rs 3,608.9 crore for the latest quarter as against Rs 3,285.6 crore in the same period of 2017-18.
The firm, last month, approved issuing equity shares of face value of Rs 10 each on a preferential basis to Cadila Healthcare, True North, Pioneer Investment Fund and Zydus Family Trust.
Atorvastatin is used in combination with diet and exercise to treat high cholesterol. It works by blocking an enzyme that is needed to make cholesterol in the body.
Net Sales are expected to decrease by 1.1 percent Y-o-Y (up 8.8 percent Q-o-Q) to Rs. 3,222.2 crore, according to ICICI Direct.
HSBC said risk-reward turned favourable post corrections in Cadila Healthcare & Cipla.
Clindamycin is an antibiotic that stops the growth of acne-causing bacteria. Benzoyl peroxide can also stop the growth of bacteria as well as reduce oil production in the skin.
Albendazole tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
Liva Pharmaceuticals, a wholly-owned subsidiary of Cadila Healthcare, has received approval from the US Food and Drug Administration (USFDA) for its supplemental abbreviated new drug application, Ranitidine Injection USP, 25 mg/mL, 2 mL single dose vials and 6 mL multi-dose vials, Cadila Healthcare said in a BSE filing.
CLSA upgraded the stock to buy from outperform as risk-reward is favourable.
The slowdown in production at Morgantown site could provide a window of opportunity to Mylan's peers
Prabhudas Lilladher recommended accumulate rating on Cadila Healthcare with a target price of Rs 371 in its research report dated November 05, 2018.
ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 415 in its research report dated November 05, 2018.
The deal, one of the largest M&A transaction in recent times, offers Zydus access to brands such as Complan, Glucon D, Nycil and Sampriti Ghee, including two manufacturing facilities and a nationwide strong distribution network
Cadila Healthcare's revenue from operations during the quarter slipped 8.1 percent to Rs 2,961.2 crore compared to Rs 3,222 crore in corresponding period last year.
The M&A transaction can be EPS accretive provided there is higher private equity or third party participation.